Literature DB >> 10767297

Transcriptional activation by the Ewing's sarcoma (EWS) oncogene can be cis-repressed by the EWS RNA-binding domain.

K K Li1, K A Lee.   

Abstract

The Ewing's sarcoma (EWS) oncogene contains an N-terminal transcriptional activation domain (EWS activation domain, EAD) and a C-terminal RNA-binding domain (RBD). Although it has been established that the EAD is a potent trans-activation domain that is required for the oncogenic activity of several EWS fusion proteins (EFPs), the precise function of the RBD and the normal role of intact EWS are poorly characterized. Here we show that a cis-linked RBD can strongly and specifically repress trans-activation by the EAD. Fusion proteins containing the RBD are expressed at normal levels, are nuclear-localized, and can bind to DNA both in vitro and in vivo, demonstrating that the RBD represses trans-activation directly at the promoter. The RNA recognition motif within the RBD is not required for repression, whereas regions of the RBD containing multiple RGG motifs play a critical role. The finding that the RBD can antagonize transcriptional activation by EWS provides the first direct evidence of a role for the RBD in transcription. Further studies of the repression phenomenon should illuminate key molecular interactions that distinguish EWS from EFPs and provide insights into the normal cellular function of EWS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10767297     DOI: 10.1074/jbc.M002961200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  In vitro interaction between the N-terminus of the Ewing's sarcoma protein and the subunit of RNA polymerase II hsRPB7.

Authors:  Roumiana Todorova
Journal:  Mol Biol Rep       Date:  2008-07-08       Impact factor: 2.316

Review 2.  The TET family of proteins: functions and roles in disease.

Authors:  Adelene Y Tan; James L Manley
Journal:  J Mol Cell Biol       Date:  2009-09-24       Impact factor: 6.216

3.  A transcription assay for EWS oncoproteins in Xenopus oocytes.

Authors:  King Pan Ng; Felix Cheung; Kevin A W Lee
Journal:  Protein Cell       Date:  2010-11-09       Impact factor: 14.870

4.  RGG boxes within the TET/FET family of RNA-binding proteins are functionally distinct.

Authors:  Bess Ling Chau; King Pan Ng; Kim K C Li; Kevin A W Lee
Journal:  Transcription       Date:  2016-05-09

5.  Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.

Authors:  Matt L Harlow; Nichole Maloney; Joseph Roland; Maria Jose Guillen Navarro; Matthew K Easton; Susan M Kitchen-Goosen; Elissa A Boguslawski; Zachary B Madaj; Ben K Johnson; Megan J Bowman; Maurizio D'Incalci; Mary E Winn; Lisa Turner; Galen Hostetter; Carlos María Galmarini; Pablo M Aviles; Patrick J Grohar
Journal:  Cancer Res       Date:  2016-10-03       Impact factor: 12.701

6.  Differential interaction of PRMT1 with RGG-boxes of the FET family proteins EWS and TAF15.

Authors:  Kim K C Li; Bess L Chau; Kevin A W Lee
Journal:  Protein Sci       Date:  2017-12-22       Impact factor: 6.725

7.  Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins.

Authors:  King Pan Ng; Gary Potikyan; Rupert O V Savene; Christopher T Denny; Vladimir N Uversky; Kevin A W Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

8.  Dr. Jekyll and Mr. Hyde: The Two Faces of the FUS/EWS/TAF15 Protein Family.

Authors:  Heinrich Kovar
Journal:  Sarcoma       Date:  2010-12-09

9.  Structure of noncoding RNA is a determinant of function of RNA binding proteins in transcriptional regulation.

Authors:  Takanori Oyoshi; Riki Kurokawa
Journal:  Cell Biosci       Date:  2012-01-03       Impact factor: 7.133

10.  RGG-boxes of the EWS oncoprotein repress a range of transcriptional activation domains.

Authors:  Deepa Alex; Kevin A W Lee
Journal:  Nucleic Acids Res       Date:  2005-03-02       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.